NEW YORK – Twist Bioscience announced on Wednesday after the close of the market the pricing of an upsized $300 million public offering of common stock at $110 per share.
The South San Francisco, California-based firm will offer approximately 2.8 million shares, including 75,000 shares to be sold by certain shareholders.
Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares at the public offering price, less the underwriting discount and commissions.
Twist initially said it planned to offer $250 million worth of shares. It expects the offering to close on or about Dec. 7, 2020, subject to customary closing conditions. Twist will not receive any proceeds from the sale of shares by the selling stockholders.
This is the third stock offering this year for the company after it raised more than $230 million in public offerings in February and June.
In morning trading on the Nasdaq, shares of Twist were up 4 percent at $119.93.